首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for up-regulation of endothelin-converting enzyme activity in disease
【2h】

Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for up-regulation of endothelin-converting enzyme activity in disease

机译:对动脉粥样硬化性人类冠状动脉中大内皮素-1的反应增加:疾病中内皮素转化酶活性上调的功能证据

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Overproduction of the potent vasoconstrictor peptide endothelin-1 (ET-1) is implicated in the pathogenesis of coronary artery disease. In endothelium-denuded human coronary arteries the response to big ET-1 was significantly enhanced in atherosclerotic arteries (coronary artery disease, CAD; n=7) with an EC50 value of 96 nM (57–161 nM, 95% C.I.) compared to 274 nM (205–365 nM) in non-diseased arteries (dilated cardiomyopathy, DCM; n=10) (Mann-Whitney U-test, P<0.05). Higher levels of immunoreactive endothelin (ET) could be detected by radioimmunoassay in bathing medium taken from CAD arteries than from DCM arteries (2.8±0.5 nM, n=5 vs 1.1±0.2 nM, n=7) (Student's two-tailed t-test, P<0.05). There were no differences in responses of arteries from either group to ET-1 (EC50 10 nM, CAD vs 14 nM, DCM). The enhanced response of atherosclerotic human coronary arteries to big ET-1 appears to be due to up-regulation of endothelin-converting enzyme (ECE) activity rather than to an augmented response of the arteries to ET-1. This non-endothelial ECE may therefore be an important therapeutic target in coronary artery disease.
机译:有效的血管收缩肽内皮素-1(ET-1)的过量生产与冠状动脉疾病的发病机理有关。在内皮剥夺的人冠状动脉中,对大ET-1的反应在动脉粥样硬化性动脉(冠状动脉疾病,CAD; n = 7)中得到显着增强,EC50值为96 valuenM(57-161 nM,95%CI)。在非病变动脉中(扩张型心肌病,DCM; n = 10)为274 nM(205-365 nM)(Mann-Whitney U检验,P <0.05)。通过放射免疫分析,在取自CAD动脉的沐浴液中可检测到比DCM动脉更高的免疫反应性内皮素(ET)水平(2.8±0.5 nM,n = 5对1.1±0.2 nM,n = 7)(学生的两尾t-测试,P <0.05)。两组患者对ET-1的动脉反应均无差异(EC50 10 nM,CAD vs 14 nM,DCM)。动脉粥样硬化性人冠状动脉对大ET-1的增强反应似乎是由于内皮素转化酶(ECE)活性上调,而不是由于动脉对ET-1增强了反应。因此,这种非内皮ECE可能是冠状动脉疾病的重要治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号